Hirschfeld Robert M. A.
Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, Galveston.
Prim Care Companion J Clin Psychiatry. 2001 Dec;3(6):244-254. doi: 10.4088/pcc.v03n0609.
Depressive and anxiety disorders commonly occur together in patients presenting in the primary care setting. Although recognition of individual depressive and anxiety disorders has increased substantially in the past decade, recognition of comorbidity still lags. The current report reviews the epidemiology, clinical implications, and management of comorbidity in the primary care setting. METHOD: Literature was reviewed by 2 methods: (1) a MEDLINE search (1980-2001) using the key words depression, depressivedisorders, and anxietydisorders; comorbidity was also searched with individual anxiety diagnoses; and (2) direct search of psychiatry, primary care, and internal medicine journals over the past 5 years. RESULTS: Between 10% and 20% of adults in any given 12-month period will visit their primary care physician during an anxiety or depressive disorder episode (although typically for a nonpsychiatric complaint); more than 50% of these patients suffer from a comorbid second depressive or anxiety disorder. The presence of depressive/anxiety comorbidity substantially increases medical utilization and is associated with greater chronicity, slower recovery, increased rates of recurrence, and greater psychosocial disability. Typically, long-term treatment is indicated, although far less research is available to guide treatment decisions. Selective serotonin reuptake inhibitor antidepressants are the preferred treatment based on efficacy, safety, and tolerability criteria. Knowledge of their differential clinical and pharmacokinetic profiles can assist in optimizing treatment. CONCLUSION: Increased recognition of the high prevalence and negative psychosocial impact of depression and anxiety disorder comorbidity will lead to more effective treatment. While it is hoped that early and effective intervention will yield long-term benefits, research is needed to confirm this.
在初级保健机构就诊的患者中,抑郁症和焦虑症常同时出现。尽管在过去十年中,对个体抑郁症和焦虑症的识别率大幅提高,但对共病的识别仍滞后。本报告回顾了初级保健机构中共病的流行病学、临床意义及管理。
通过两种方法对文献进行回顾:(1)利用关键词“抑郁症”“抑郁障碍”和“焦虑障碍”对MEDLINE(1980 - 2001年)进行检索;共病情况也与各个焦虑诊断一同检索;(2)直接检索过去5年的精神病学、初级保健和内科医学期刊。
在任何给定的12个月期间,10%至20%的成年人会在焦虑或抑郁发作期间去看初级保健医生(尽管通常是因非精神科主诉);这些患者中超过50%患有第二种抑郁或焦虑共病障碍。抑郁/焦虑共病的存在显著增加了医疗资源的利用,并与更高的慢性病程度、更慢的康复速度、更高的复发率以及更大的心理社会残疾相关。通常需要长期治疗,尽管可用于指导治疗决策的研究少得多。基于疗效、安全性和耐受性标准,选择性5-羟色胺再摄取抑制剂类抗抑郁药是首选治疗药物。了解它们不同的临床和药代动力学特征有助于优化治疗。
对抑郁症和焦虑症共病的高患病率及负面心理社会影响的认识提高,将带来更有效的治疗。虽然希望早期有效干预能产生长期益处,但仍需要研究来证实这一点。